Stryker has adjusted its 2025 profit outlook to between 9.5% and 10%, up from 8.5%-9.5%, amid strong growth in its medical surgery and neurotechnology unit.
With profits of $6bn for Q2 2025, an 11.1% rise from $5.4bn in Q2 2024, the Michigan-based company now expects an adjusted profit of $13.40 to $13.60 per share for 2025.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Stryker’s financials revealed total sales of $3.7bn in its medical surgery and neurotechnology business unit, up 17.3% on Q2 2024.
While the medical segment reported total sales of $990m, a 9% uplift on the segment’s $908m performance in Q2 2024, the vascular segment was by far the most significant sales driver, increasing by 52.3% to $498m versus $327m in Q2 2024.
The significant growth is likely due to Stryker’s $4.9bn acquisition of peripheral vascular specialist Inari Medical in February 2025. This sets the stage for the company to challenge the market’s established players, including Boston Scientific and Terumo.
Signalling Stryker’s entry into the peripheral vascular device market, the acquisition of Inari adds the US-based company’s FlowTriever System for treating pulmonary embolism and the ClotTriever System for thrombectomy in the peripheral vessels to Stryker’s neurotechnology portfolio.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to GlobalData analysis, the global peripheral vascular devices market is growing at a CAGR of 4.6% and is projected to reach a valuation of around $18.3bn by 2034, up from $11.7bn in 2024.
Due to rising rates of peripheral artery diseases worldwide, including deep vein thrombosis and pulmonary embolism, the acquisition is likely to strengthen Stryker’s position in the overall cardiovascular device market, as per GlobalData analysis.
Elsewhere in the business, in Q2 2025, Stryker’s orthopaedics unit achieved sales of $2.2bn, marking a 2% rise on Q2 2024. Trauma and extremities saw the biggest growth at 15% to $957m, versus $832m in Q2 2024, suggesting that Stryker’s $5.4bn acquisition of upper extremities specialist Wright Medical in 2019 is continuing to pay dividends.
Commenting on its Q2 2025 performance, Stryker chairman and CEO Kevin A Lobo commented: “Our strong sales and earnings power reflect demand for our products, our durable innovation pipeline and ongoing operational execution.”
